RxDoctor Payments Data

Osawaru Omoruyi, MD

Family Medicine · Louisville, KYNPI 1396961967

Payments from drug & device makers

$443in general payments, 2019–2025

Across 11 payments — averaging $40.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$120
  • Johnson & Johnson$114
  • E.r. Squibb & Sons, L.L.C.$93
  • AstraZeneca$83
  • Merck$18
  • Siemens Medical Solutions USA, Inc.$14

What the payments were for

  • Food & beverage$443100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$443 in reported general payments places this provider in the 40th percentile of 1,559 family medicine providers in Kentucky.

See all family medicine providers in Kentucky

Medicare billing

Part B allowed, 2024
$469,284
Medicare patients
799
Services billed
4,795

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,366$477,311
OxycontinOxycodone Hcl100$139,588
XareltoRivaroxaban254$94,368
Xeljanz XrTofacitinib Citrate13$79,466
XifaxanRifaximin37$67,880
Trelegy ElliptaFluticasone/Umeclidin/Vilanter87$58,899
LinzessLinaclotide88$52,097
OzempicSemaglutide48$46,293
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen1,202$44,426
GemtesaVibegron152$43,879
Invega SustennaPaliperidone Palmitate18$39,167
GilenyaFingolimod Hcl11$37,930
OrenciaAbatacept22$37,644
JardianceEmpagliflozin88$36,936
Divalproex Sodium604$34,285

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto, Invega Sustenna, Procrit$114$152,123305 claims
Novo NordiskOzempic$120$46,29348 claims
E.r. Squibb & Sons, L.L.C.Orencia$93$37,64422 claims
AstraZenecaFarxiga, Symbicort$83$33,92396 claims
MerckJanuvia$18$29,89581 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 1,559 family medicine providers in Kentucky.

Other family medicine in Louisville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →